Journal of Affective Disorders
February 2018
Gerrit I Van Schalkwyk, Samuel T. Wilkinson, Larry Davidson et al.
Ketamine has rapid-acting antidepressant effects. Frequently, ketamine administration also causes acute psychoactive effects - in trials, these effects are commonly measured using the Clinician Administered Dissociative State Scale (CADSS). However, the CADSS was not designed for this specific purpose, having been validated in other clinical contexts, and anecdotally does not appear to fully...
Journal of Psychopharmacology
February 2018
Haiying Tang, Daniel Kukral, Yu-Wen Li et al.
Major depressive disorder is a leading cause of disability globally. Improvements in the efficacy of antidepressant therapy are needed as a high proportion (>40%) of individuals with major depressive disorder fail to respond adequately to current treatments. The non-selective N-methyl-D-aspartate receptor channel blocker, (±)-ketamine, has been reported to produce a rapid and long-lasting...
Experimental and Clinical Psychopharmacology
February 1, 2018
Michael Mathews, R. N. Mead, M. Galizio
The glutamate hypothesis proposes that N-Methyl-D-aspartate (NMDA) receptor hypofunction underlies cognitive and perhaps other schizophrenic symptoms. The present study used the odor span task to assess the effects of NMDA antagonists on remembering multiple stimuli in rodents. This task uses an incrementing nonmatching-to-sample procedure in which responses to a new olfactory stimulus are...
Psychopharmacology
February 1, 2018
Liana Fattore, Alessandro Piva, Mary Tresa Zanda et al.
Clinical data with 3,4-methylenedioxymethamphetamine (MDMA) in post-traumatic stress disorder (PTSD) patients recently stimulated interest on the potential therapeutic use of psychedelics in disorders characterized by maladaptive memories, including substance use disorders (SUD). The rationale for the use of MDMA in PTSD and SUD is being extended to a broader beneficial "psychedelic effect,"...
Psychopharmacology
February 1, 2018
John Hartberg, Simone Garrett-Walcott, Angelo De Gioannis
66 citations
Depressive episodes are the leading cause of mental health-related hospital admissions in Australia, and 44% of those admitted have a previous history of hospitalisations for depression (Admitted patient mental health-related care: (Australian Institute of Health and Welfare Aust Hospital Stat 2011-12, 2013). Despite numerous available antidepressant treatments, many patients do not respond to...
Journal of Clinical Pharmacy and Therapeutics
January 25, 2018
Ji‐Hye Kwon, Woo-Seok Sim, Jhuo Hong et al.
5 citations
WHAT IS KNOWN AND OBJECTIVE: Ketamine in a subanaesthetic dose has been shown to produce rapid antidepressant effects. Here, we describe a long-term follow-up case of a Korean patient with severe major depression who received repeated ketamine intravenous therapy (KIT). CASE DESCRIPTION: A 49-year-old woman with a 6-year history of treatment-resistant major depression was given KIT once every 1...
Frontiers in Pharmacology
January 15, 2018
Kristian Du Jardin, Nico Liebenberg, M. Cajina et al.
Rationale: The mechanisms responsible for the unique antidepressant properties of ketamine have only been partly resolved. Recent preclinical reports implicate the neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] in the antidepressant-like response of ketamine, and modulation of 5-HT1B receptors has been hypothesized to attain an important role. Objectives: To evaluate the role of...
Proceedings for Annual Meeting of The Japanese Pharmacological Society
2018
Soichiro Ide, Yuiko Ikekubo, Masayoshi Mishina et al.
Background: The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine exerts rapid and sustained antidepressant effects in depressed patients. Ketamine is a racemic mixture of equal amounts of enantiomers, (R)-ketamine and (S)-ketamine. The neural mechanisms that underlie different effects of these enantiomers remain unclear.
Developmental Psychobiology
January 2018
Carlos Coronel-Oliveros, Renny Pacheco-Calderón
Schizophrenia is a complex neuropsychiatric disorder characterized by hallucinations, delusions, anhedonia, flat affect and cognitive impairments. The aim of this study was to propose a prenatal treatment with ketamine, a psychedelic drug that acts as a non-competitive inhibitor of glutamate NMDA receptors, as a neurodevelopmental animal model of schizophrenia. The drug was applied (i.m. 60...
Pharmacognosy Magazine
2018
Ken Kin Lam Yung, Zhixian Mo, Youli Guo et al.
12 citations
BACKGROUND: species that is well known for both its potent anti-addictive and neuroprotective properties. Increasing evidence supports the contributions of cAMP response element binding protein (CREB), nuclear receptor-related-1 (Nurr1), and brain-derived neurotrophic factor (BDNF) in modulating neural and behavioral plasticity which was induced by addictive drugs. OBJECTIVE: To investigate the...